Drug Approval | February 24, 2026
FDA approves Lilly's Zepbound multi-dose KwikPen for obesity treatment
In 2025, over 1 million patients accessed Lilly treatments through LillyDirect
In 2025, over 1 million patients accessed Lilly treatments through LillyDirect
If approved, DTX401 would be the first treatment to address the disease at its root cause
UBT251 appeared to have a safe and well-tolerated profile consistent with incretin-based therapies
Both non-transfusion-dependent and transfusion dependent cohorts met their respective primary and secondary endpoints
The drug’s safety profile in LIBRETTO-432 aligned with previous selpercatinib studies, showing no unexpected concerns
The results mark a potential breakthrough for patients living with CIndU, a condition with limited treatment options
Wegovy is now offered in six weekly doses in the EU: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg, and the newly approved 7.2 mg dose
The trial, which compared Retevmo to placebo, met its primary endpoint with a “highly statistically significant and clinically meaningful improvement” in investigator-assessed EFS for patients with stage II–IIIA disease
Vanrafia, a potent endothelin A receptor antagonist, received accelerated approval in the US and China in 2025 for reducing proteinuria in adults with IgAN
Alto met its enrollment goal with 83 patients across 13 US clinical sites
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
